Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing

The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient's leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect p...

Descripción completa

Detalles Bibliográficos
Autores principales: Noaks, Elsa, Peticone, Carlotta, Kotsopoulou, Ekaterini, Bracewell, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917474/
https://www.ncbi.nlm.nih.gov/pubmed/33718517
http://dx.doi.org/10.1016/j.omtm.2021.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917474/
https://www.ncbi.nlm.nih.gov/pubmed/33718517
http://dx.doi.org/10.1016/j.omtm.2021.02.002

Ejemplares similares